Table 1.
Baseline Patient Demographics and Disease Characteristics
| Characteristics | Cohort A, KRAS-mt NSCLC (N = 25) | Cohort B, Squamous NSCLC (N = 25) |
|---|---|---|
| Sex, n (%) | ||
| Male | 11 (44.0) | 21 (84.0) |
| Female | 14 (56.0) | 4 (16.0) |
| Age, y | ||
| Median (range) | 62 (36–80) | 60 (42–73) |
| Race, n (%) | ||
| White | 21 (84.0) | 12 (48.0) |
| Asian | 0 | 5 (20.0) |
| Black or African American | 0 | 1 (4.0) |
| Not reported | 4 (16.0) | 7 (28.0) |
| ECOG PS, n (%) | ||
| 0 | 9 (36.0) | 8 (32.0) |
| 1 | 16 (64.0) | 17 (68.0) |
| Smoking status, n (%) | ||
| Current | 7 (28.0) | 4 (16.0) |
| Past | 17 (68.0) | 21 (84.0) |
| Never | 1 (4.0) | 0 |
| Duration of disease from initial diagnosis, mo | ||
| Median (range) | 1.9 (0.7–27.1) | 7.4 (2.0–50.9) |
| Previous systemic therapy, n (%) | NA | 25 (100.0) |
| Metastatic disease, n (%) | NA | 21 (84.0)a |
| PD-L1 status, n (%) | ||
| Strong (≥50%) | 13 (52.0) | 2 (8.0) |
| Weak (1%–49%) | 12 (48.0) | 3 (12.0) |
| Negative | 0 | 16 (64.0) |
| NA | 0 | 4 (16.0) |
| KRAS mutation status | ||
| G12C | 13 (52.0) | NA |
| G12V | 5 (20.0) | NA |
| Others | 7 (28.0) | NA |
ECOG PS, Eastern Cooperative Oncology Group performance status; KRAS-mt, KRAS-mutant; n, number of subjects in the specified category; N, number of subjects in safety population; NA, not applicable; PD-L1, programmed death-ligand 1.
a
Four patients had disease progression within 6 months since the last dose of chemotherapy in the (neo)adjuvant setting.